Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Trial Profile

Phase Ib Clinical Trial of Buparlisib and Ibrutinib in Mantle Cell Lymphoma, Follicular Lymphoma and Diffuse Large B Cell Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Sep 2017

At a glance

  • Drugs Buparlisib (Primary) ; Ibrutinib
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Jun 2017 Results (n=13, data cut off: Dec 16, 2016) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 18 Aug 2016 Status changed from not yet recruiting to recruiting.
    • 05 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top